reviewed april 2026|next review october 2026|88 physicians psi has verified|38645 published studies
ARA-290
ARA-290 (cibinetide) is an 11-amino acid peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor for tissue protection and neuroprotection without stimulating red blood cell production, with Phase II clinical trial data in sarcoidosis and diabetic neuropathy.
Evidence landscape: 38645 published studies
Published studies include Phase II clinical trials and laboratory characterization. The innate repair receptor biology is well-documented.
- 14 Human
- 151 Animal
- 35 Reviews
- 38445 Other research
Captures the tissue-protective effects of EPO without the erythropoietic (blood-thickening) effects. Activates the innate repair receptor (EPOR/CD131 heterodimer) rather than the classical EPO receptor.
Phase II trials in sarcoidosis-associated neuropathy showed pain reduction. Diabetic neuropathy studies showed improved corneal nerve fiber density. Safety profile is favorable.
Not FDA-approved. Phase II completed. Phase III confirmation has not been conducted.
PSI Assessment
EPO is widely known for stimulating red blood cell production, but it also has tissue-protective effects that are medically useful. The problem is that giving EPO for tissue protection also thickens the blood, creating stroke and clotting risks. ARA-290 (cibinetide) was engineered to capture only the tissue-protective side by activating a different receptor entirely. Phase II trials showed pain reduction in sarcoidosis neuropathy and improved nerve fiber density in diabetic neuropathy. The open question is whether Phase III trials will confirm these signals.
Captures EPO's tissue-protective effects without blood-thickening risks. Phase II data shows pain reduction in sarcoidosis neuropathy and nerve fiber improvement in diabetic neuropathy.
The innate repair receptor (IRR) is a heterodimer of the EPO receptor and beta common receptor (CD131). ARA-290 selectively activates this receptor, triggering anti-apoptotic signaling through the JAK2/STAT5 pathway and suppressing NF-kB-mediated inflammation. Unlike EPO, ARA-290 does not bind the classical erythropoietic receptor configuration, so it produces no red blood cell stimulation. Phase II results are encouraging for neuropathic pain and small-fiber neuropathy restoration.
What the evidence supports
Phase II trial data demonstrates pain reduction in sarcoidosis-associated neuropathy. Corneal nerve fiber density improvement observed in diabetic neuropathy studies. The innate repair receptor (IRR) mechanism is well-characterized and distinct from erythropoietic EPO signaling.
What is not yet established
Phase III efficacy confirmation in any indication. Whether benefits extend beyond the specific neuropathy populations tested. Long-term durability of neuroprotective effects. Comparison to existing neuropathy treatments.
Research Evidence
The findings below cover the innate repair receptor mechanism, Phase II neuropathy results, and the safety profile in human studies.
Evidence by condition
Evidence dimensions across ARA-290's investigated applications. Neuropathic pain and diabetic neuropathy have Phase II human data.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Sarcoidosis Neuropathy | ||||
| Diabetic Neuropathy | ||||
| Neuroprotection (General) |
ARA-290 selectively activates the innate repair receptor (EPOR/CD131 heterodimer), triggering tissue-protective signaling without stimulating red blood cell production. This receptor is pharmacologically distinct from the classical erythropoietic EPO receptor.
The receptor selectivity is the core innovation. It resolves the clinical problem of needing EPO's tissue protection without its blood-thickening risk.
A Phase II trial in sarcoidosis-associated neuropathy demonstrated statistically significant pain reduction compared to placebo. Patients also showed improvement in small-fiber neuropathy markers.
Sarcoidosis neuropathy is a difficult-to-treat condition. A positive signal in this population is clinically meaningful but requires Phase III confirmation.
In diabetic neuropathy studies, ARA-290 improved corneal nerve fiber density, a structural biomarker of small-fiber neuropathy. This suggests actual nerve repair rather than symptom masking.
Improving nerve fiber density is structurally significant. Most neuropathy treatments manage pain without addressing the underlying nerve damage.
14 Human|151 Animal|35 Reviews
View all 38645 indexed studiesHow ARA-290 Works
ARA-290 (cibinetide) is an 11-amino acid peptide derived from helix B of erythropoietin that selectively activates the innate repair receptor (EPOR/CD131 heterodimer) for tissue protection without erythropoietic stimulation.
EPO is known for making red blood cells but also protects tissues. ARA 290 captures only the tissue protection. Activates a different receptor (innate repair receptor) that triggers nerve repair and reduces inflammation, without making more blood cells.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
ARA-290 is derived from the helix B surface of EPO. It binds the innate repair receptor (IRR), a heterodimer of EPOR and CD131 (beta common receptor). Activation triggers JAK2/STAT5 anti-apoptotic signaling, suppresses NF-kB inflammatory cascades, promotes Schwann cell survival and neuronal repair, and drives macrophage polarization toward the M2 anti-inflammatory phenotype. The IRR has lower affinity for EPO than the classical EPOR homodimer, which is why tissue-protective EPO doses overlap with erythropoietic doses. ARA-290 resolves this by binding IRR selectively.
What is ARA-290 being studied for?
Researchers are studying ARA-290 across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for ARA-290 overall. This means a compound can have human studies for one condition but only animal data for another.
Sarcoidosis Neuropathy
·Human TrialsPhase II trial demonstrated statistically significant pain reduction and improvement in small-fiber neuropathy markers in sarcoidosis patients.
Limitations: Phase III confirmation is not available. Sample sizes are small. Whether the effects are durable beyond the study period is unknown.
Diabetic Neuropathy
·Human TrialsImproved corneal nerve fiber density, a structural biomarker of small-fiber neuropathy, suggesting actual nerve repair rather than symptom management.
Limitations: Early-stage human data. Whether structural nerve improvement translates to sustained clinical benefit requires larger and longer studies.
Neuroprotection (General)
·Animal StudiesThe innate repair receptor mechanism supports nerve repair independent of erythropoiesis. Animal models demonstrate neuroprotection across multiple injury types.
Limitations: Clinical applications beyond the specific neuropathy indications tested are theoretical.
Safety and Regulatory Status
FDA Status: Not FDA-approved for any indication. Phase II trials completed.
Availability: Investigational compound. Not available through clinical or pharmacy channels.
Class context: Well tolerated in Phase II human studies with no significant adverse events. Unlike EPO, produces no red blood cell stimulation or blood-thickening effects.
Favorable safety profile in Phase II human studies. No significant adverse events reported. The key safety advantage over EPO is the absence of erythropoietic stimulation, eliminating the stroke and clotting risks associated with EPO therapy.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a ARA-290 discussion.
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Described the identification of the innate repair receptor (IRR) and the development of ARA-290 as a tissue-protective peptide derived from the EPO molecule that does not stimulate red blood cell production.Brines M et al., 2008 in Mol Med. View on PubMed
- 2.Phase II trial demonstrating that ARA-290 reduced pain scores and increased corneal nerve fiber density in patients with sarcoidosis-associated small fiber neuropathy, providing the first human evidence of nerve repair.Dahan A et al., 2013 in Pain. View on PubMed
- 3.Reported improvements in small-fiber neuropathy markers in diabetic patients treated with ARA-290, demonstrating that innate repair receptor activation can promote nerve regeneration in humans without stimulating red blood cell production.Brines M et al., 2015 in Mol Med. View on PubMed
- 4.Confirmed that ARA-290 (cibinetide) improved objective measures of nerve fiber density on confocal microscopy in sarcoidosis patients, supporting the mechanism of actual nerve regeneration rather than symptom suppression.Culver DA et al., 2017 in Neurology. View on PubMed
- 5.Review describing the innate repair receptor as a distinct EPO receptor variant that mediates tissue protection without erythropoietic activity, establishing the scientific rationale for ARA-290.Brines M & Cerami A, 2012 in Nat Rev Drug Discov. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.